Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The use of bolus insulin and advancing insulin therapy in type 2 diabetes.

Literature DB >> 15461900

The use of bolus insulin and advancing insulin therapy in type 2 diabetes.

Abstract

Attention to meal-related insulin replacement in type 2 diabetes is important as insulin deficiency progresses. The physiology in type 2 and type 1 diabetes differs, and optimal use of basal-bolus therapy in type 2 diabetes requires attention to such issues as the role for oral medications, residual endogenous insulin, and differing meal patterns in older and more obese individuals.

Entities: Disease Gene

Mesh：

Substances：

Year: 2004 PMID： 15461900 DOI： 10.1007/s11892-004-0037-1

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

27 in total

1. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

Authors: E J Bastyr; C A Stuart; R G Brodows; S Schwartz; C J Graf; A Zagar; K E Robertson
Journal: Diabetes Care Date: 2000-09 Impact factor: 19.112

2. Combination of insulin and metformin in the treatment of type 2 diabetes.

Authors: Michiel G Wulffelé; Adriaan Kooy; Philippe Lehert; Daniel Bets; Jeles C Ogterop; Bob Borger van der Burg; Ab J M Donker; Coen D A Stehouwer
Journal: Diabetes Care Date: 2002-12 Impact factor: 19.112

3. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.

Authors: S R Mudaliar; F A Lindberg; M Joyce; P Beerdsen; P Strange; A Lin; R R Henry
Journal: Diabetes Care Date: 1999-09 Impact factor: 19.112

4. Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

Authors: W T Cefalu; J S Skyler; I A Kourides; W H Landschulz; C C Balagtas; S Cheng; R A Gelfand
Journal: Ann Intern Med Date: 2001-02-06 Impact factor: 25.391

5. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.

Authors: Kjeld Hermansen; Michele Colombo; Heidi Storgaard; Anette ØStergaard; Klaus Kølendorf; Sten Madsbad
Journal: Diabetes Care Date: 2002-05 Impact factor: 19.112

6. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.

Authors: H Yki-Järvinen; L Ryysy; K Nikkilä; T Tulokas; R Vanamo; M Heikkilä
Journal: Ann Intern Med Date: 1999-03-02 Impact factor: 25.391

7. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Authors: Mark S Fineman; Thomas A Bicsak; Larry Z Shen; Kristin Taylor; Eling Gaines; Amanda Varns; Dennis Kim; Alain D Baron
Journal: Diabetes Care Date: 2003-08 Impact factor: 19.112

8. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.

Authors: L Landstedt-Hallin; U Adamson; P Arner; J Bolinder; P E Lins
Journal: Diabetes Care Date: 1995-08 Impact factor: 19.112

The use of bolus insulin and advancing insulin therapy in type 2 diabetes.

1. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

2. Combination of insulin and metformin in the treatment of type 2 diabetes.

3. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.

4. Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

5. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.

6. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.

7. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

8. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.

9. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial.

10. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.

1. Starting insulin therapy in type 2 diabetes: lesson 1.

Review 2. What are the best options for controlling prandial glycemia?

3. Comparing the efficacy, safety, and utility of intensive insulin algorithms for a primary care practice.

4. Insulin initiation and intensification in patients with T2DM for the primary care physician.